Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients
Chronic spontaneous urticaria (CSU) is a debilitating disorder.[...]well-defined therapeutic strategies are required to achieve a maximal remission and maintain quality of life.The first involves highly cytokinergic monomeric IgEs, which by binding Fc region of immunoglobulin E receptor I (FcɛRI) in...
Gespeichert in:
| Veröffentlicht in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2017-11, Vol.5 (6), p.1743-1745 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1745 |
|---|---|
| container_issue | 6 |
| container_start_page | 1743 |
| container_title | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
| container_volume | 5 |
| creator | Vadasz, Zahava Tal, Yuval Rotem, Menachem Shichter-Confino, Vered Mahlab-Guri, Keren Graif, Yael Kessel, Aharon Agmon-Levin, Nancy Maoz-Segal, Ramit Kivity, Shmuel Benor, Shira Lachover-Roth, Idit Zeldin, Yuri Stein, Migel Toker, Ori Hassoun, Gamal Bezalel-Rosenberg, Shira Toubi, Elias Asher, Ilan Sthoeger, Zev |
| description | Chronic spontaneous urticaria (CSU) is a debilitating disorder.[...]well-defined therapeutic strategies are required to achieve a maximal remission and maintain quality of life.The first involves highly cytokinergic monomeric IgEs, which by binding Fc region of immunoglobulin E receptor I (FcɛRI) in the absence of antigens induce mast cell activation and histamine release.6 The second is the binding of autoreactive antibodies on activated skin mast cells.[...]we suggest that the fast onset of response to omalizumab could be explained by the rapid sequestration of monomeric-free IgEs and the silencing of mast cell degranulation.Hsieh, S. Saini, C. Grattan, A. Gimenez-Arnau, Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria, N Engl J Med, Vol. 368, 2013, 924-935 4 T. Zuberbier, W. Aberer, R. Asero, C. Bindslev-Jensen, Z. Brzoza, G.W. Canonica, 2, Allergy, Vol. 69, 2014, 868-887 5 M. Metz, T. Ohanyan, M.K. Church, M. Maurer, Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis, J Dermato Sci, Vol. 73, 2013, 57-62 6 J. Kashiwakura, Y. Okayama, M. Furue, K. Kabashima, S. Shimada, C. Ra, Most highly cytokinergic IgEs have polyreactivity to autoantigens, Allergy Asthma Immunol Res, Vol. 4, 2012, 332-340 7 T.W. Chang, C. Chen, C.J. Lin, M. Metz, M.K. Church, M. Maurer, The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria, J Allergy Clin Immunol, Vol. 135, 2015, 337-342 8 A.P. Kaplan, A.M. Gimenez-Arnau, S.S. Saini, Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria, Allergy, Vol. 72, 2017, 519-533 9 M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, S. Seyfried, Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase, J Allergy Clin Immunol, Vol. 128, 2011, 202-209.e5 |
| doi_str_mv | 10.1016/j.jaip.2017.08.035 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1949087766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213219817307195</els_id><sourcerecordid>1965442738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-6ac0fee1b3c4f342d3859f863dcce2ce53d4d4c73dcab34a51c83028ff3f08e13</originalsourceid><addsrcrecordid>eNp9kM1L5jAQh4MoKq7_gIcl4MVLu_lqO128iOwXCILoxUvIm07YlLbpJq24_vWbd1_1sIedSybDMz-Gh5AzzkrOeP2pL3vj51Iw3pQMSiarPXIsBJeFyLP9t563cEROU-pZLuANU-yQHAloARqoj8nj7WgG_7KOZkNdiDThE0ak9mcMk7c0zWFazIRhTXSNi7cmevOZ3qEZisE7pPg8Y_Q4WUw0OCqA0dksebCkD-TAmSHh6et7Qh6-frm__l7c3H77cX11U1gJailqY5lD5BtplZNKdBKq1kEtO2tRWKxkpzplm_w3G6lMxS1IJsA56RgglyfkYpc7x_BrxbTo0SeLw7C7W_NWtQyapq4zev4P2oc1Tvm6TNWVUqKRkCmxo2wMKUV0eo5-NPG35kxv5eteb-XrrXzNQGf5eenja_S6GbF7X3lTnYHLHYDZxZPHqJP9K67zEe2iu-D_l_8H0iaVoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1965442738</pqid></control><display><type>article</type><title>Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients</title><source>Alma/SFX Local Collection</source><creator>Vadasz, Zahava ; Tal, Yuval ; Rotem, Menachem ; Shichter-Confino, Vered ; Mahlab-Guri, Keren ; Graif, Yael ; Kessel, Aharon ; Agmon-Levin, Nancy ; Maoz-Segal, Ramit ; Kivity, Shmuel ; Benor, Shira ; Lachover-Roth, Idit ; Zeldin, Yuri ; Stein, Migel ; Toker, Ori ; Hassoun, Gamal ; Bezalel-Rosenberg, Shira ; Toubi, Elias ; Asher, Ilan ; Sthoeger, Zev</creator><creatorcontrib>Vadasz, Zahava ; Tal, Yuval ; Rotem, Menachem ; Shichter-Confino, Vered ; Mahlab-Guri, Keren ; Graif, Yael ; Kessel, Aharon ; Agmon-Levin, Nancy ; Maoz-Segal, Ramit ; Kivity, Shmuel ; Benor, Shira ; Lachover-Roth, Idit ; Zeldin, Yuri ; Stein, Migel ; Toker, Ori ; Hassoun, Gamal ; Bezalel-Rosenberg, Shira ; Toubi, Elias ; Asher, Ilan ; Sthoeger, Zev ; The Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU) ; Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU)</creatorcontrib><description>Chronic spontaneous urticaria (CSU) is a debilitating disorder.[...]well-defined therapeutic strategies are required to achieve a maximal remission and maintain quality of life.The first involves highly cytokinergic monomeric IgEs, which by binding Fc region of immunoglobulin E receptor I (FcɛRI) in the absence of antigens induce mast cell activation and histamine release.6 The second is the binding of autoreactive antibodies on activated skin mast cells.[...]we suggest that the fast onset of response to omalizumab could be explained by the rapid sequestration of monomeric-free IgEs and the silencing of mast cell degranulation.Hsieh, S. Saini, C. Grattan, A. Gimenez-Arnau, Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria, N Engl J Med, Vol. 368, 2013, 924-935 4 T. Zuberbier, W. Aberer, R. Asero, C. Bindslev-Jensen, Z. Brzoza, G.W. Canonica, 2, Allergy, Vol. 69, 2014, 868-887 5 M. Metz, T. Ohanyan, M.K. Church, M. Maurer, Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis, J Dermato Sci, Vol. 73, 2013, 57-62 6 J. Kashiwakura, Y. Okayama, M. Furue, K. Kabashima, S. Shimada, C. Ra, Most highly cytokinergic IgEs have polyreactivity to autoantigens, Allergy Asthma Immunol Res, Vol. 4, 2012, 332-340 7 T.W. Chang, C. Chen, C.J. Lin, M. Metz, M.K. Church, M. Maurer, The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria, J Allergy Clin Immunol, Vol. 135, 2015, 337-342 8 A.P. Kaplan, A.M. Gimenez-Arnau, S.S. Saini, Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria, Allergy, Vol. 72, 2017, 519-533 9 M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, S. Seyfried, Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase, J Allergy Clin Immunol, Vol. 128, 2011, 202-209.e5</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2017.08.035</identifier><identifier>PMID: 28988786</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Dermatitis ; Drug dosages ; Drug therapy ; Immunoglobulin E ; Immunotherapy ; Monoclonal antibodies ; Urticaria</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-11, Vol.5 (6), p.1743-1745</ispartof><rights>2017 American Academy of Allergy, Asthma & Immunology</rights><rights>2017. American Academy of Allergy, Asthma & Immunology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-6ac0fee1b3c4f342d3859f863dcce2ce53d4d4c73dcab34a51c83028ff3f08e13</citedby><cites>FETCH-LOGICAL-c384t-6ac0fee1b3c4f342d3859f863dcce2ce53d4d4c73dcab34a51c83028ff3f08e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28988786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vadasz, Zahava</creatorcontrib><creatorcontrib>Tal, Yuval</creatorcontrib><creatorcontrib>Rotem, Menachem</creatorcontrib><creatorcontrib>Shichter-Confino, Vered</creatorcontrib><creatorcontrib>Mahlab-Guri, Keren</creatorcontrib><creatorcontrib>Graif, Yael</creatorcontrib><creatorcontrib>Kessel, Aharon</creatorcontrib><creatorcontrib>Agmon-Levin, Nancy</creatorcontrib><creatorcontrib>Maoz-Segal, Ramit</creatorcontrib><creatorcontrib>Kivity, Shmuel</creatorcontrib><creatorcontrib>Benor, Shira</creatorcontrib><creatorcontrib>Lachover-Roth, Idit</creatorcontrib><creatorcontrib>Zeldin, Yuri</creatorcontrib><creatorcontrib>Stein, Migel</creatorcontrib><creatorcontrib>Toker, Ori</creatorcontrib><creatorcontrib>Hassoun, Gamal</creatorcontrib><creatorcontrib>Bezalel-Rosenberg, Shira</creatorcontrib><creatorcontrib>Toubi, Elias</creatorcontrib><creatorcontrib>Asher, Ilan</creatorcontrib><creatorcontrib>Sthoeger, Zev</creatorcontrib><creatorcontrib>The Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU)</creatorcontrib><creatorcontrib>Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU)</creatorcontrib><title>Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>Chronic spontaneous urticaria (CSU) is a debilitating disorder.[...]well-defined therapeutic strategies are required to achieve a maximal remission and maintain quality of life.The first involves highly cytokinergic monomeric IgEs, which by binding Fc region of immunoglobulin E receptor I (FcɛRI) in the absence of antigens induce mast cell activation and histamine release.6 The second is the binding of autoreactive antibodies on activated skin mast cells.[...]we suggest that the fast onset of response to omalizumab could be explained by the rapid sequestration of monomeric-free IgEs and the silencing of mast cell degranulation.Hsieh, S. Saini, C. Grattan, A. Gimenez-Arnau, Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria, N Engl J Med, Vol. 368, 2013, 924-935 4 T. Zuberbier, W. Aberer, R. Asero, C. Bindslev-Jensen, Z. Brzoza, G.W. Canonica, 2, Allergy, Vol. 69, 2014, 868-887 5 M. Metz, T. Ohanyan, M.K. Church, M. Maurer, Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis, J Dermato Sci, Vol. 73, 2013, 57-62 6 J. Kashiwakura, Y. Okayama, M. Furue, K. Kabashima, S. Shimada, C. Ra, Most highly cytokinergic IgEs have polyreactivity to autoantigens, Allergy Asthma Immunol Res, Vol. 4, 2012, 332-340 7 T.W. Chang, C. Chen, C.J. Lin, M. Metz, M.K. Church, M. Maurer, The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria, J Allergy Clin Immunol, Vol. 135, 2015, 337-342 8 A.P. Kaplan, A.M. Gimenez-Arnau, S.S. Saini, Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria, Allergy, Vol. 72, 2017, 519-533 9 M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, S. Seyfried, Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase, J Allergy Clin Immunol, Vol. 128, 2011, 202-209.e5</description><subject>Dermatitis</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Immunoglobulin E</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>Urticaria</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kM1L5jAQh4MoKq7_gIcl4MVLu_lqO128iOwXCILoxUvIm07YlLbpJq24_vWbd1_1sIedSybDMz-Gh5AzzkrOeP2pL3vj51Iw3pQMSiarPXIsBJeFyLP9t563cEROU-pZLuANU-yQHAloARqoj8nj7WgG_7KOZkNdiDThE0ak9mcMk7c0zWFazIRhTXSNi7cmevOZ3qEZisE7pPg8Y_Q4WUw0OCqA0dksebCkD-TAmSHh6et7Qh6-frm__l7c3H77cX11U1gJailqY5lD5BtplZNKdBKq1kEtO2tRWKxkpzplm_w3G6lMxS1IJsA56RgglyfkYpc7x_BrxbTo0SeLw7C7W_NWtQyapq4zev4P2oc1Tvm6TNWVUqKRkCmxo2wMKUV0eo5-NPG35kxv5eteb-XrrXzNQGf5eenja_S6GbF7X3lTnYHLHYDZxZPHqJP9K67zEe2iu-D_l_8H0iaVoQ</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Vadasz, Zahava</creator><creator>Tal, Yuval</creator><creator>Rotem, Menachem</creator><creator>Shichter-Confino, Vered</creator><creator>Mahlab-Guri, Keren</creator><creator>Graif, Yael</creator><creator>Kessel, Aharon</creator><creator>Agmon-Levin, Nancy</creator><creator>Maoz-Segal, Ramit</creator><creator>Kivity, Shmuel</creator><creator>Benor, Shira</creator><creator>Lachover-Roth, Idit</creator><creator>Zeldin, Yuri</creator><creator>Stein, Migel</creator><creator>Toker, Ori</creator><creator>Hassoun, Gamal</creator><creator>Bezalel-Rosenberg, Shira</creator><creator>Toubi, Elias</creator><creator>Asher, Ilan</creator><creator>Sthoeger, Zev</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201711</creationdate><title>Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients</title><author>Vadasz, Zahava ; Tal, Yuval ; Rotem, Menachem ; Shichter-Confino, Vered ; Mahlab-Guri, Keren ; Graif, Yael ; Kessel, Aharon ; Agmon-Levin, Nancy ; Maoz-Segal, Ramit ; Kivity, Shmuel ; Benor, Shira ; Lachover-Roth, Idit ; Zeldin, Yuri ; Stein, Migel ; Toker, Ori ; Hassoun, Gamal ; Bezalel-Rosenberg, Shira ; Toubi, Elias ; Asher, Ilan ; Sthoeger, Zev</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-6ac0fee1b3c4f342d3859f863dcce2ce53d4d4c73dcab34a51c83028ff3f08e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Dermatitis</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Immunoglobulin E</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>Urticaria</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vadasz, Zahava</creatorcontrib><creatorcontrib>Tal, Yuval</creatorcontrib><creatorcontrib>Rotem, Menachem</creatorcontrib><creatorcontrib>Shichter-Confino, Vered</creatorcontrib><creatorcontrib>Mahlab-Guri, Keren</creatorcontrib><creatorcontrib>Graif, Yael</creatorcontrib><creatorcontrib>Kessel, Aharon</creatorcontrib><creatorcontrib>Agmon-Levin, Nancy</creatorcontrib><creatorcontrib>Maoz-Segal, Ramit</creatorcontrib><creatorcontrib>Kivity, Shmuel</creatorcontrib><creatorcontrib>Benor, Shira</creatorcontrib><creatorcontrib>Lachover-Roth, Idit</creatorcontrib><creatorcontrib>Zeldin, Yuri</creatorcontrib><creatorcontrib>Stein, Migel</creatorcontrib><creatorcontrib>Toker, Ori</creatorcontrib><creatorcontrib>Hassoun, Gamal</creatorcontrib><creatorcontrib>Bezalel-Rosenberg, Shira</creatorcontrib><creatorcontrib>Toubi, Elias</creatorcontrib><creatorcontrib>Asher, Ilan</creatorcontrib><creatorcontrib>Sthoeger, Zev</creatorcontrib><creatorcontrib>The Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU)</creatorcontrib><creatorcontrib>Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU)</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vadasz, Zahava</au><au>Tal, Yuval</au><au>Rotem, Menachem</au><au>Shichter-Confino, Vered</au><au>Mahlab-Guri, Keren</au><au>Graif, Yael</au><au>Kessel, Aharon</au><au>Agmon-Levin, Nancy</au><au>Maoz-Segal, Ramit</au><au>Kivity, Shmuel</au><au>Benor, Shira</au><au>Lachover-Roth, Idit</au><au>Zeldin, Yuri</au><au>Stein, Migel</au><au>Toker, Ori</au><au>Hassoun, Gamal</au><au>Bezalel-Rosenberg, Shira</au><au>Toubi, Elias</au><au>Asher, Ilan</au><au>Sthoeger, Zev</au><aucorp>The Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU)</aucorp><aucorp>Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2017-11</date><risdate>2017</risdate><volume>5</volume><issue>6</issue><spage>1743</spage><epage>1745</epage><pages>1743-1745</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>Chronic spontaneous urticaria (CSU) is a debilitating disorder.[...]well-defined therapeutic strategies are required to achieve a maximal remission and maintain quality of life.The first involves highly cytokinergic monomeric IgEs, which by binding Fc region of immunoglobulin E receptor I (FcɛRI) in the absence of antigens induce mast cell activation and histamine release.6 The second is the binding of autoreactive antibodies on activated skin mast cells.[...]we suggest that the fast onset of response to omalizumab could be explained by the rapid sequestration of monomeric-free IgEs and the silencing of mast cell degranulation.Hsieh, S. Saini, C. Grattan, A. Gimenez-Arnau, Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria, N Engl J Med, Vol. 368, 2013, 924-935 4 T. Zuberbier, W. Aberer, R. Asero, C. Bindslev-Jensen, Z. Brzoza, G.W. Canonica, 2, Allergy, Vol. 69, 2014, 868-887 5 M. Metz, T. Ohanyan, M.K. Church, M. Maurer, Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis, J Dermato Sci, Vol. 73, 2013, 57-62 6 J. Kashiwakura, Y. Okayama, M. Furue, K. Kabashima, S. Shimada, C. Ra, Most highly cytokinergic IgEs have polyreactivity to autoantigens, Allergy Asthma Immunol Res, Vol. 4, 2012, 332-340 7 T.W. Chang, C. Chen, C.J. Lin, M. Metz, M.K. Church, M. Maurer, The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria, J Allergy Clin Immunol, Vol. 135, 2015, 337-342 8 A.P. Kaplan, A.M. Gimenez-Arnau, S.S. Saini, Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria, Allergy, Vol. 72, 2017, 519-533 9 M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, S. Seyfried, Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase, J Allergy Clin Immunol, Vol. 128, 2011, 202-209.e5</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28988786</pmid><doi>10.1016/j.jaip.2017.08.035</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-2198 |
| ispartof | The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-11, Vol.5 (6), p.1743-1745 |
| issn | 2213-2198 2213-2201 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1949087766 |
| source | Alma/SFX Local Collection |
| subjects | Dermatitis Drug dosages Drug therapy Immunoglobulin E Immunotherapy Monoclonal antibodies Urticaria |
| title | Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A48%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Omalizumab%20for%20severe%20chronic%20spontaneous%20urticaria:%20Real-life%20experiences%20of%20280%20patients&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Vadasz,%20Zahava&rft.aucorp=The%20Israeli%20Forum%20for%20investigating%20and%20treating%20Chronic%20Spontaneous%20Urticaria%20(CSU)&rft.date=2017-11&rft.volume=5&rft.issue=6&rft.spage=1743&rft.epage=1745&rft.pages=1743-1745&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2017.08.035&rft_dat=%3Cproquest_cross%3E1965442738%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1965442738&rft_id=info:pmid/28988786&rft_els_id=S2213219817307195&rfr_iscdi=true |